Exchange-traded funds (ETFs) have long been a popular option for investors who don’t want to be tied to particular companies. While ETFs are traded like stocks, they are made up of baskets of assets — including stocks, bonds and commodities — and can give investors more flexibility.  
No cannabis ETFs exist at the moment, but a strong push is being made to create at least two of them. Midway through February, ETF Managers Trust filed paperwork to list a cannabis ETF on the NYSE Arca. According to MarketWatch, it will be called the Emerging AgroSphere ETF, and will track medical cannabis companies that produce or sell hemp-based products. It will also track companies focused on researching cannabidiol and cannabis use in prescription drugs.
A cannabis ETF in Canada is gaining some traction as well. In late February, Horizons ETFs Management filed a preliminary proposal to list the Horizons Medical Life Sciences ETF on the TSX. It will provide exposure to “North American publicly listed life sciences companies in the marijuana industry,” says Advisor.ca. Read on to learn more about these two proposed ETFs and what they could mean for cannabis in the US and Canada.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Cannabis ETFs: Emerging AgroSphere

As mentioned, ETF Managers Trust’s proposed ETF will focus on medical marijuana companies, at least initially. It explains in its filing with the US Securities and Exchange Commission that the ETF won’t invest in companies that serve the non-medical marijuana markets in the US, Canada “or any other country unless and until such time as the production and sale of non-medical marijuana becomes legal in the United States, Canada, or any other such country, respectively.”
The ETF will be made up of approximately 69 companies, including: GW Pharmaceuticals (OTCMKTS:GWPRF) and Abbot Laboratories (NYSE:ABT).
While some investors may be disappointed that the ETF won’t focus on the non-medical marijuana market, it’s worth noting that the medical cannabis space is expected to grow significantly in the coming years. In the US the medical marijuana market could be valued at $21.6 billion by 2021, up from $6.9 billion in 2016.
The Emerging AgroSphere ETF hasn’t been approved yet, and its ticker symbol and potential launch date are still unknown.


Cannabis ETFs: Horizons ETFs Management

The Horizons Medical Life Sciences ETF will also reportedly be focused on medical, not recreational, marijuana companies. BNN says it will attempt to track Solactive’s North American Medical Marijuana Index, and “is expected to include 18 companies from a variety of subsectors, including biopharmaceuticals, medical manufacturing, distribution, bio products and other ancillary businesses related to the marijuana industry.”
It also has not been approved and does not have a launch date; however, Horizons ETFs Management has said it will trade under the symbol HMMJ.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Cannabis ETFs: Potential risks

While excitement is bubbling about both proposed ETFs, some experts are warning investors to exercise caution.
For one thing, the future of marijuana in the US under Trump is still uncertain. The Hill recently reported that members of his administration have said they plan to enforce more strict drug laws. “I’m dubious about marijuana. I’m not sure we’re going to be a better, healthier nation if we have marijuana sold at every corner grocery store,” the news outlet quotes Attorney General Jeff Sessions as saying.
Additionally, Khurram Malik, head of research at Jacob Capital Management, told BNN that it’s possible that the proposed cannabis ETFS “might not be the pure play investors might be looking for in the marijuana space.”
“A few other ETFs will be launching in the next little while later on this year, as well,” he explained. “The tricky thing is, can you put enough constituents to put into the ETF to meet those really strict requirements in terms of liquidity hurdles, in terms of market cap hurdles, et cetera.”
Similarly, Advisor.ca notes that investors interested in the Horizons Medical Life Sciences ETF will have to make transactions on a smaller exchange, which can mean less liquidity, more volatility and more expensive transaction fees, as well as settlement delays.
For now, investors would do well to watch for more information about both proposed ETFs. If they pan out as hoped, it certainly will bode well for a prosperous future in the industry.
Don’t forget to follow us @INN_Resource for real-time news updates.
Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article. 

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

THC-O-Acetate to be Produced Through Company’s Specialty Molecule Division

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), an extraction company that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids, is pleased to announce the launch of a Specialty Molecules Division to focus on the development and commercialization of novel psychoactive compounds. The division is supported by the Company’s existing intellectual property (“IP”) portfolio, including the manufacturing of CBD-O-acetate and the recently announced U.S. patent for the synthesis of THC-O-acetate.

Keep reading... Show less

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (the “Company”) is pleased to announce that it has completed construction of an industrial-grade distribution site and launched third party distribution services.

As part of its Phase 1 Construction project at the 196,000 square foot facility, the Company has built out 16,000 square feet of retail-ready product storage space, installed automated, assembly-line style packaging equipment for jar and pouch production, and built out a climate-controlled area that can store 30 tractor-trailer loads of cannabis and 230 pallets positions of -40 degree Fahrenheit freezers for storing live resin and live resin products. A secure loading bay and a small in-house fleet of refrigerated trucks is also in place.

Keep reading... Show less

Global Wellness Strategies Inc. (CSE: LOAN) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“GWS” or the “Company”) is pleased to provide the following corporate update highlights on two portfolio clients KaleidoMyco LLC and Biominerales Pharma Corp. and announces the signing of the one-stop digital marketing team of North Equities Corp.

“With the talent, skills and resources we have at Global Wellness, we are well positioned to develop leading nutraceutical product portfolio brands focused on health and well-being. As hemp-extract and psilocybin is legalized in more jurisdictions such as Oregon where we already have a strong strategic relationship, we can then easily extend our existing product range, which will already have established routes to market and brand recognition, to include myco-dosing products. KaleidoMyco products will be in stores and on a consumer digital platform in the USA shortly and is currently being consumer tested in Europe as well. Our shareholders and customers are extremely important to us and we look forward to meeting the milestones we have outlined with the help of North Equities,” said Meris Kott, CEO.

Keep reading... Show less

VINIA(R)’s ability to increase dilation of arteries and to reduce blood vessel constriction allows it to fight the human aging process

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) announces that its flagship VINIA® product is the only dietary supplement available in the US market which has the capability for both reducing the endothelin 1 (ET1) enzyme as well as increasing the nitric oxide (NO) molecules, in order to increase the dilation of arteries and thereby improve blood flow. The presence of ET1 constricts the blood vessel, whereas the presence of NO dilates it. As a result of its “double-action” effect (proven by the Flow Mediated Dilatation (FMD) measurements in a double-blinded Placebo-controlled clinical trial*and in an in-vitro study** whose results were both published), VINIA® is uniquely positioned to combat the aging process caused by a reduction in blood flow.

Keep reading... Show less

Combined Company Highlights:

  • Experienced management team with a well-established brand portfolio
  • A highly sought after Colorado processing license in good standing
  • Bronnor adds one of the largest GMP-compliant cannabis processing and
    manufacturing facilities in Colorado
  • Distribution network of 1,200+ dispensaries across four states
  • Four high-profile THC and CBD brands

INDVR Brands, Inc. (CSE: IDVR) (the “Company” or “INDVR Brands” or “INDVR”), a premier cannabis brand house and edibles producer, is pleased to announce that it has completed the previously announced Asset Purchase Agreement (“APA”)of substantially all assets of Nevada based Strainz, Inc. and Colorado-based Bronnor, Corp. through its wholly owned subsidiary, INDVR Brands U.S., Inc, and the addition of Hugh Hempel as President & COO with a pending appointment to the Board of Directors at its next Annual Meeting of Shareholders on July 27, 2021.

Keep reading... Show less